Pfizer's Stock Rebound and Oncology Push: Is the Pharma Giant Undervalued?
Pfizer's shares have staged a notable rebound in recent months, drawing investor attention as the company pivots towards oncology. We examine whether the current valuation reflects its long-term growth potential or lingering post-pandemic challenges.